Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
OraSure Technologies, Inc. is a diagnostics company focused on the development, manufacture, and commercialization of point-of-care, rapid, and molecular diagnostic products. The company operates primarily within the in vitro diagnostics and infectious disease testing industries, serving healthcare providers, public health organizations, laboratories, employers, and consumers. Its core value proposition centers on non-invasive sample collection and rapid testing technologies designed to improve access, speed, and reliability of diagnostic information.
OraSure’s primary revenue drivers include rapid diagnostic tests for infectious diseases and molecular sample collection devices used in laboratory-based testing. The company is best known for the OraQuick® brand of rapid tests, particularly for HIV and hepatitis C, and for its molecular collection products used in genomics and precision medicine workflows. Founded in 1987 and originally operating under different corporate entities before a 2000 merger that formed the current company, OraSure has evolved from a niche oral-fluid testing company into a diversified diagnostics platform with both clinical and consumer-facing products.
Business Operations
OraSure operates through two primary business segments: Diagnostics and Molecular Solutions. The Diagnostics segment includes rapid antigen and antibody tests for infectious diseases such as HIV, hepatitis C, and COVID-19, generating revenue through sales to public health agencies, hospitals, and retail channels. The Molecular Solutions segment focuses on oral and saliva-based collection devices that enable downstream DNA and RNA analysis, with revenue largely driven by sales to research institutions, clinical laboratories, and commercial testing partners.
The company conducts most of its manufacturing and product development activities in the United States, while distributing products internationally through a combination of direct sales and third-party distributors. OraSure controls proprietary technologies related to oral fluid and saliva collection, lateral flow immunoassays, and rapid diagnostics. Key subsidiaries include DNAGenotek, which specializes in molecular sample collection devices, and OraSure International, which supports global distribution and regulatory activities.
Strategic Position & Investments
OraSure’s strategic direction emphasizes expanding access to decentralized and at-home diagnostics, strengthening its infectious disease testing portfolio, and growing its molecular collection business tied to genomics and personalized medicine. A major strategic move was the acquisition of InteliSwab® rapid antigen test assets from Cellectis in 2021, which expanded OraSure’s capabilities in rapid COVID-19 testing and scalable lateral flow manufacturing.
The company has continued to invest in product innovation, regulatory approvals, and manufacturing automation to improve margins and responsiveness to public health needs. DNAGenotek remains a key strategic subsidiary, supporting OraSure’s exposure to emerging sectors such as population genomics, biobanking, and precision health. While OraSure has explored partnerships in molecular diagnostics and infectious disease surveillance, publicly available sources indicate no large transformational acquisitions beyond InteliSwab in recent years.
Geographic Footprint
OraSure is headquartered in Bethlehem, Pennsylvania, and maintains its primary operational and manufacturing footprint in the United States. The company has an established international presence, with products distributed across Europe, Asia, Africa, and Latin America, primarily through government tenders, global health organizations, and regional distributors.
Internationally, OraSure’s diagnostics are used extensively in public health programs, particularly for HIV and hepatitis C screening in resource-limited settings. Through DNAGenotek, the company also supports molecular research and clinical testing customers in Canada, Western Europe, and parts of Asia-Pacific, giving OraSure a diversified global revenue base and exposure to both developed and emerging healthcare markets.
Leadership & Governance
OraSure is led by an executive team with experience in diagnostics, life sciences, and regulated healthcare markets. The company emphasizes disciplined capital allocation, product quality, and expanding access to diagnostics through innovation and partnerships. Leadership has articulated a strategic vision focused on decentralized testing, operational efficiency, and long-term value creation rather than short-term volume-driven growth.
Key executives include:
- Carrie Eglinton Manner – President and Chief Executive Officer
- Ken McCreedy – Chief Financial Officer
- Rachael McClain – Chief Legal Officer and Corporate Secretary
- Douglas A. Michels – Founder and Board Member
- Mark R. Galli – Chief Operating Officer
The board and management team oversee corporate governance in line with U.S. public company standards, with oversight of regulatory compliance, risk management, and strategic execution.